Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
Mallinckrodt C, Tian Y, Aisen PS, Barkhof F, Cohen S, Dent G, Hansson O, Harrison K, Iwatsubo T, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, von Hehn C, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A, Chen T, Budd Haeberlein S.
Mallinckrodt C, et al. Among authors: dent g.
J Prev Alzheimers Dis. 2023;10(2):171-177. doi: 10.14283/jpad.2023.6.
J Prev Alzheimers Dis. 2023.
PMID: 36946443
Clinical Trial.